Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. (November 2020)

• Record Type: Journal Article
• Authors: Eggermont, Alexander M.M.; Bellomo, Domenico; Arias-Mejias, Suzette M.; Quattrocchi, Enrica; Sominidi-Damodaran, Sindhuja; Bridges, Alina G.; Lehman, Julia S.; Hieken, Tina J.; Jakub, James W.; Murphree, Dennis H.; Pittelkow, Mark R.; Sluzevich, Jason C.; Cappel, Mark A.; Bagaria, Sanjay P.; Perniciaro, Charles; Tjien-Fooh, Félicia J.; Rentroia-Pacheco, Barbara; Wever, Renske; van Vliet, Martin H.; Dwarkasing, Jvalini; Meves, Alexander
• Is Part Of: European journal of cancer. Volume 140(2020)
• Page Start: 11
• Page End: 18
• Publication Date: 2020-11
• Subjects: Primary cutaneous melanoma -- Relapse-free survival -- Metastasis -- Prognostic biomarkers -- Clinicopathologic -- Gene expression variables -- CP-GEP; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2020.08.029
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Purpose: Patients with stage I/IIA cutaneous melanoma (CM) are currently not eligible for adjuvant therapies despite uncertainty in relapse risk. Here, we studied the ability of a recently developed model which combines clinicopathologic and gene expression variables (CP-GEP) to identify stage I/IIA melanoma patients who have a high risk for disease relapse. Patients and methods: Archival specimens from a cohort of 837 consecutive primary CMs were used for assessing the prognostic performance of CP-GEP. The CP-GEP model combines Breslow thickness and patient age, with the expression of eight genes in the primary tumour. Our specific patient group, represented by 580 stage I/IIA patients, was stratified based on their risk of relapse: CP-GEP High Risk and CP-GEP Low Risk. The main clinical end-point of this study was five-year relapse-free survival (RFS). Results: Within the stage I/IIA melanoma group, CP-GEP identified a high-risk patient group (47% of total stage I/IIA patients) which had a considerably worse five-year RFS than the low-risk patient group; 74% (95% confidence interval [CI]: 67%–80%) versus 89% (95% CI: 84%–93%); hazard ratio [HR] = 2.98 (95% CI: 1.78–4.98); P < 0.0001. Of patients in the high-risk group, those who relapsed were most likely to do so within the first 3 years. Conclusion: The CP-GEP model can be used to identify stage I/IIA patients who have a high risk for disease relapse. These patients may benefit from adjuvant therapy. Highlights: Prognostic performance assessment of CP-GEP primary cutaneous melanoma patients. The CP-GEP model combines clinicopathologic and gene expression variables. A cohort comprised of 837 prospectively collected archived primary melanomas. CP-GEP identifies stage I/IIA patients who are at high risk for disease relapse. CP-GEP High Risk patients may benefit from adjuvant therapy.